Journal
MOLECULES
Volume 22, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/molecules22101551
Keywords
MEK inhibitors; targeted therapy; combination; approved drug; clinical study; preclinical study
Funding
- Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, and Fundamental Research Fund for CAMSPUMC [2016ZX310199, 1649]
- CAMS Innovation Fund for Medical Sciences (CIFMS) from Chinese Academy of Medical Sciences & Peking Union Medical College [2017-I2M-3-019]
Ask authors/readers for more resources
The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer. Moreover, the combination of the MEK inhibitors with other therapies-such as chemotherapy, targeted therapy, and immunotherapy-may be a promising approach for clinical use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
